Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature

被引:60
作者
Bergk, V
Haefeli, WE
Gasse, C
Brenner, H
Martin-Facklam, M
机构
[1] Univ Heidelberg, Dept Internal Med 6, D-69120 Heidelberg, Germany
[2] Univ Heidelberg, German Ctr Res Ageing, Dept Epidemiol, D-69115 Heidelberg, Germany
关键词
drug interactions; drug labelling; summary of product characteristics;
D O I
10.1007/s00228-005-0943-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To compare comprehensiveness and accuracy of drug interaction information in the German summary of product characteristics (SPC) with current evidence from the literature and to evaluate the SPC's usefulness with respect to management of drug interactions. Methods: Information on clinically relevant drug interactions was compared between the SPC and three standard information sources on drug interactions (DRUGDEX, Hansten/Horn's Drug Interactions Analysis and Management, Stockley's Drug Interactions) according to five consecutive criteria (inclusion, appropriateness of class labelling, effect description, management recommendation, explicit dose adjustment). Using medication data of an outpatient population (n=4,949), we determined what percentage of insufficiently characterized combinations indeed occurred in outpatients treated with combination drug therapy. Results: Only for 33% (192/579) of the evaluated combinations did SPCs provide drug interaction information equivalent to the evidence from the published literature. Of the clinically relevant drug interactions, 16% were completely missing and 51% were insufficiently characterized compared with standard sources. Explicit management recommendations were either missing or differed from standard sources in 18% of the evaluated pairs of compounds. Of these missing or insufficiently characterized combinations, 12% (47/387) were indeed prescribed to outpatients. Those drug combinations for which the interaction potential was not mentioned in the SPC were received by 0.6% (32/4,949) of patients, and 4% (192/4,949) of patients received combinations that had insufficiently characterized drug interactions. Conclusions: If physicians only rely on SPC information for drug interactions, adverse events due to lacking management recommendations may occur. To meet the SPCs claim of being the basis of information for health professionals on how to use medicinal products safely and effectively, information on drug interactions should be thoroughly up-dated and expanded.
引用
收藏
页码:327 / 335
页数:9
相关论文
共 24 条
[11]   Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management? [J].
Martin-Facklam, M ;
Rengelshausen, J ;
Tayrouz, Y ;
Ketabi-Kiyanvash, N ;
Lindenmaier, H ;
Schneider, V ;
Bergk, V ;
Haefeli, WE .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (11) :807-811
[12]   General practitioners' perceptions of the route to evidence based medicine: a questionnaire survey [J].
McColl, A ;
Smith, H ;
White, P ;
Field, J .
BRITISH MEDICAL JOURNAL, 1998, 316 (7128) :361-365
[13]   DRUG-INTERACTIONS THAT MATTER - A CRITICAL REAPPRAISAL [J].
MCINNES, GT ;
BRODIE, MJ .
DRUGS, 1988, 36 (01) :83-110
[14]   Incorrect overdose management advice in the Physicians' desk reference [J].
Mullen, WH ;
Anderson, IB ;
Kim, SY ;
Blanc, PD ;
Olson, KR .
ANNALS OF EMERGENCY MEDICINE, 1997, 29 (02) :255-261
[15]   CLINICAL-PHARMACOLOGY OF PRAVASTATIN, A SELECTIVE INHIBITOR OF HMG-COA REDUCTASE [J].
PAN, HY .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 :S15-S18
[16]   Influences on GPs' decision to prescribe new drugs - the importance of who says what [J].
Prosser, H ;
Almond, S ;
Walley, T .
FAMILY PRACTICE, 2003, 20 (01) :61-68
[17]   Drug labeling should be kept current [J].
Rajpal, A ;
Reidenberg, MM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (01) :4-6
[19]   Prescribing information in 26 countries:: a comparative study [J].
Reggi, V ;
Balocco-Mattavelli, R ;
Bonati, M ;
Breton, I ;
Figueras, A ;
Jambert, E ;
Kopp, C ;
Montane, E ;
Rägo, L ;
Rocchi, F .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (04) :263-270
[20]  
Rosholm JU, 1998, DAN MED BULL, V45, P210